MIM
IMDX

MetLife Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

MetLife Investment Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,448
Closed -$166K – 2578
2021
Q2 		$166K Buy
1,448
+1,361
+1,564% +$133K ﹤0.01% 2268
2021
Q1 		$9.03K Buy
+87
New +$8.26K ﹤0.01% 2309

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's IMDX Position: Q3 2021 in Review

MetLife Investment Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2021, closing a stake of 1,448 shares — an estimated $166K sold.

MetLife Investment Management first reported a position in IMDX in Q1 2021 and held it in 2 quarters. The position peaked at $166K in Q2 2021. 95 funds tracked by Wall St. Rank hold IMDX as of Q3 2021.

  • MetLife Investment Management reported no remaining Insight Molecular Diagnostics position as of Q3 2021 after selling out during the quarter.
  • MetLife Investment Management sold 1,448 Insight Molecular Diagnostics shares in Q3 2021, an estimated $166K.
  • MetLife Investment Management first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 2 quarters.
  • MetLife Investment Management's Insight Molecular Diagnostics position peaked at $166K in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2021.

Based on MetLife Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.